专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09994634B2 Use of an IL-17/IL-23 bispecific antibody for treating inflammation 有权
公开(公告)号：US09994634B2
公开(公告)日：2018-06-12
申请号：US15260059
申请日：2016-09-08
申请人： ZymoGenetics, Inc.
发明人： Katherine E. Lewis , Scott R. Presnell , Steven D. Levin , Robert Mabry , Stephen R. Jaspers , Monica J. Huber
IPC分类号： A61K39/395 , C07K16/24 , A61K39/00
CPC分类号： C07K16/244 , A61K2039/505 , A61K2039/507 , C07K2317/14 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92 , Y10S530/809
摘要： The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and IL-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.

2. 发明申请

US20160311897A1 MONOCLONAL ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F 审中-公开
标题翻译： BILD IL-17A和IL-17F的单克隆抗体
公开(公告)号：US20160311897A1
公开(公告)日：2016-10-27
申请号：US15208202
申请日：2016-07-12
申请人： ZymoGenetics, Inc.
发明人： Stephen R. Jaspers , Scott R. Presnell , Monica J. Huber
IPC分类号： C07K16/24
CPC分类号： C07K16/244 , A61K2039/505 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/52 , C07K2317/76 , C07K2317/92 , C07K2319/30 , G01N33/6869 , G01N2333/54 , Y10S530/809
摘要： The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.
摘要翻译：本发明涉及阻断，抑制，降低，拮抗或中和IL-17A和IL-17F的活性。 IL-17A和IL-17F是参与炎症过程和人类疾病的细胞因子。本发明包括结合IL-17A和IL-17F的抗体，产生抗体的杂交瘤，以及在炎症中使用该抗体的方法。

3. 发明授权

US09388241B2 Anti-human IL-21 antibodies 有权
标题翻译：抗人IL-21抗体
公开(公告)号：US09388241B2
公开(公告)日：2016-07-12
申请号：US13492315
申请日：2012-06-08
申请人： Pallavur V. Sivakumar , Stephen R. Jaspers
发明人： Pallavur V. Sivakumar , Stephen R. Jaspers
IPC分类号： A61K39/395 , C07K16/22 , C07K16/24 , C07K16/18 , A61K39/00
CPC分类号： C07K16/244 , A61K39/3955 , A61K2039/505 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2319/30 , Y10S530/809
摘要： Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and inflammatory diseases such as pancreatitis, type I diabetes (IDDM), Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, rheumatoid arthritis, diverticulosis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, scleroderma, systemic sclerosis, psoriatic arthritis, osteoarthritis, atopic dermatitis, vitiligo, graft vs. host disease (GVHD), cutaneous T cell lymphoma (CTCL), Sjogren's syndrome, glomerulonephritis, IgA nephropathy, transplant rejection, atopic dermatitis, anti-phospholipid syndrome, and asthma, and other autoimmune diseases.
摘要翻译：鉴定结合IL-21蛋白的单克隆抗体。这些抗体用于鉴定结合中和IL-21活性的IL-21蛋白的区域。描述了杂交瘤和产生抗IL-21单克隆抗体的方法。单克隆抗体可用于治疗IL-21介导的疾病，其可能包括自身免疫性和炎性疾病如胰腺炎，I型糖尿病（IDDM），格雷夫斯病，炎性肠病（IBD），克罗恩病，溃疡性结肠炎，肠易激综合征综合征，多发性硬化症，类风湿性关节炎，憩室病，系统性红斑狼疮，牛皮癣，强直性脊柱炎，硬皮病，系统性硬化症，银屑病关节炎，骨关节炎，特应性皮炎，白癜风，移植物抗宿主病（GVHD），皮肤T细胞淋巴瘤，干燥综合征，肾小球性肾炎，IgA肾病，移植排斥反应，特应性皮炎，抗磷脂综合征，哮喘和其他自身免疫性疾病。

4. 发明申请

US20140170154A1 ENGINEERED ANTI-IL-23R ANTIBODIES 审中-公开
标题翻译：工程抗IL-23R抗体
公开(公告)号：US20140170154A1
公开(公告)日：2014-06-19
申请号：US14181350
申请日：2014-02-14
申请人： MERCK SHARP & DOHME CORP.
发明人： Leonard G. Presta
IPC分类号： C07K16/24
CPC分类号： C07K16/244 , C07K16/2866 , C07K2317/24 , C07K2317/76 , C07K2317/92 , Y10S530/809
摘要： Antibodies to human IL-23R are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.
摘要翻译：提供了人IL-23R的抗体及其用途，例如治疗炎症，自身免疫和增殖性疾病。

5. 发明申请

US20140134103A1 TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS 审中-公开
标题翻译：治疗和预防乳腺增生症
公开(公告)号：US20140134103A1
公开(公告)日：2014-05-15
申请号：US14099692
申请日：2013-12-06
申请人： Dale B. SCHENK , Peter A. Seubert , Jonathan Wall , José Saldanha
发明人： Dale B. SCHENK , Peter A. Seubert , Jonathan Wall , José Saldanha
IPC分类号： C07K16/18 , A61K39/00 , A61K49/16 , A61K49/00 , A61K51/10
CPC分类号： A61K39/0008 , A61K49/00 , A61K49/16 , A61K51/1018 , A61K2039/505 , C07K16/18 , C07K2317/24 , C07K2317/32 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/92 , Y10S530/809
摘要： Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
摘要翻译：通过施用包含新表皮的肽，例如来自AA的C末端区域的AA片段和对聚集的淀粉样蛋白的新表皮特异的抗体，例如抗体，可用于预防或治疗淀粉样变性（包括AA淀粉样变性和AL淀粉样变性）的方法特异于AA原纤维的C-末端区域。用于抑制形成和/或增加患者淀粉样沉积物清除率的抗体，从而实现预防或治疗淀粉样蛋白病。

6. 发明授权

US08636981B2 Detection of amyloid deposits using anti-amyloid antibodies 有权
标题翻译：使用抗淀粉样蛋白抗体检测淀粉样蛋白沉积物
公开(公告)号：US08636981B2
公开(公告)日：2014-01-28
申请号：US13314160
申请日：2011-12-07
申请人： Dale B. Schenk , Peter A. Seubert , Jonathan Wall
发明人： Dale B. Schenk , Peter A. Seubert , Jonathan Wall
IPC分类号： A61B5/055 , A61B5/05 , A61K49/16 , A61K51/10
CPC分类号： C07K16/18 , A61K39/0008 , A61K49/00 , A61K49/16 , A61K51/1018 , A61K2039/505 , C07K2317/24 , C07K2317/32 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/92 , Y10S530/809
摘要： Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
摘要翻译：通过施用包含新表皮的肽，例如来自AA的C末端区域的AA片段和对聚集的淀粉样蛋白的新表皮特异的抗体，例如抗体，可用于预防或治疗淀粉样变性（包括AA淀粉样变性和AL淀粉样变性）的方法特异于AA原纤维的C-末端区域。用于抑制形成和/或增加患者淀粉样沉积物清除率的抗体，从而实现预防或治疗淀粉样蛋白病。

7. 发明授权

US08496936B2 Antagonists of IL-17A, IL-17F, and IL-23P19 有权
公开(公告)号：US08496936B2
公开(公告)日：2013-07-30
申请号：US13534019
申请日：2012-06-27
申请人： Katherine E. Lewis , Scott R. Presnell , Steven D. Levin , Robert Mabry , Stephen R. Jaspers , Monica J. Huber
发明人： Katherine E. Lewis , Scott R. Presnell , Steven D. Levin , Robert Mabry , Stephen R. Jaspers , Monica J. Huber
IPC分类号： A61K39/00 , A61K39/395
CPC分类号： C07K16/244 , A61K2039/505 , A61K2039/507 , C07K2317/14 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92 , Y10S530/809
摘要： The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.

8. 发明授权

US08187594B2 Transferrin receptor antibodies 有权
标题翻译：转铁蛋白受体抗体
公开(公告)号：US08187594B2
公开(公告)日：2012-05-29
申请号：US12483774
申请日：2009-06-12
申请人： Jennie P. Mather , Penelope E. Roberts , Ronghao Li
发明人： Jennie P. Mather , Penelope E. Roberts , Ronghao Li
IPC分类号： A61K39/395 , A61K39/00 , C07K16/00 , C12P21/08
CPC分类号： C07K16/2881 , A61K39/39533 , A61K2039/505 , C07K16/2863 , C07K2317/77 , Y10S530/808 , Y10S530/809 , A61K2300/00
摘要： The invention provides further characterization of the disease and cancer-associated antigen, transferrin receptor. The invention also provides a novel family of antibodies that bind to the transferrin receptor, methods of diagnosing and treating various human cancers and diseases that express transferrin receptor.
摘要翻译：本发明提供了疾病和癌症相关抗原转铁蛋白受体的进一步表征。本发明还提供了结合转铁蛋白受体的新型抗体家族，诊断和治疗表达转铁蛋白受体的各种人类癌症和疾病的方法。

9. 发明申请

US20120039878A1 TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS 有权
标题翻译：治疗和预防乳腺增生症
公开(公告)号：US20120039878A1
公开(公告)日：2012-02-16
申请号：US13187093
申请日：2011-07-20
申请人： Dale B. Schenk , Peter A. Seubert , Jonathan Wall , José W. Saldanha
发明人： Dale B. Schenk , Peter A. Seubert , Jonathan Wall , José W. Saldanha
IPC分类号： A61K39/395 , C07K16/00 , C12N5/10
CPC分类号： C07K16/18 , A61K39/0008 , A61K49/00 , A61K49/16 , A61K51/1018 , A61K2039/505 , C07K2317/24 , C07K2317/32 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/92 , Y10S530/809
摘要： Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
摘要翻译：通过施用包含新表皮的肽，例如来自AA的C末端区域的AA片段和对聚集的淀粉样蛋白的新表皮特异的抗体，例如抗体，可用于预防或治疗淀粉样变性（包括AA淀粉样变性和AL淀粉样变性）的方法特异于AA原纤维的C-末端区域。用于抑制形成和/或增加患者淀粉样沉积物清除率的抗体，从而实现预防或治疗淀粉样蛋白病。

10. 发明申请

US20110224408A1 TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS 审中-公开
公开(公告)号：US20110224408A1
公开(公告)日：2011-09-15
申请号：US13032507
申请日：2011-02-22
申请人： Dale B. SCHENK , Peter A. Seubert , Jonathan Wall , José W. Saldanha
发明人： Dale B. SCHENK , Peter A. Seubert , Jonathan Wall , José W. Saldanha
IPC分类号： C07K16/18
CPC分类号： A61K39/0008 , A61K49/00 , A61K49/16 , A61K51/1018 , A61K2039/505 , C07K16/18 , C07K2317/24 , C07K2317/32 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/92 , Y10S530/809
摘要： Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式